Negative News SentimentNegative NewsNASDAQ:BVS Bioventus (BVS) Stock Price, News & Analysis $6.90 -0.03 (-0.43%) As of 02:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsFinancialsSEC FilingsShort InterestTrendsBuy This Stock About Bioventus Stock (NASDAQ:BVS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bioventus alerts:Sign Up Key Stats Today's Range$6.77▼$7.2150-Day Range N/A52-Week Range$5.81▼$14.38Volume220,185 shsAverage Volume393,978 shsMarket Capitalization$566.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina. Read More Bioventus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreBVS MarketRank™: Bioventus scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Bioventus. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Bioventus is -14.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bioventus is -14.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioventus has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.53% of the float of Bioventus has been sold short.Short Interest Ratio / Days to CoverBioventus has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bioventus has recently decreased by 2.45%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioventus does not currently pay a dividend.Dividend GrowthBioventus does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.53% of the float of Bioventus has been sold short.Short Interest Ratio / Days to CoverBioventus has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bioventus has recently decreased by 2.45%, indicating that investor sentiment is improving. News and Social Media1.4 / 5News SentimentN/A News SentimentBioventus has a news sentiment score of -1.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.13 average news sentiment score of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 1 news article for Bioventus this week, compared to 0 articles on an average week.Search Interest2 people have searched for BVS on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Bioventus to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bioventus insiders have not sold or bought any company stock.Percentage Held by Insiders33.00% of the stock of Bioventus is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.94% of the stock of Bioventus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bioventus' insider trading history. Receive BVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioventus and its competitors with MarketBeat's FREE daily newsletter. Email Address BVS Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com BVS Stock Analysis - Frequently Asked Questions How have BVS shares performed this year? Bioventus' stock was trading at $6.26 on January 1st, 2025. Since then, BVS stock has increased by 10.1% and is now trading at $6.89. How were Bioventus' earnings last quarter? Bioventus Inc. (NASDAQ:BVS) announced its quarterly earnings data on Wednesday, August, 6th. The company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.22 by $0.01. Bioventus had a negative net margin of 0.03% and a positive trailing twelve-month return on equity of 23.51%. When did Bioventus IPO? Bioventus (BVS) raised $126 million in an IPO on Thursday, February 11th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity served as the underwriters for the IPO. How do I buy shares of Bioventus? Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/06/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Surgical, Medical, And Dental Instruments And Supplies Sub-IndustryMedical Equipment Current SymbolNASDAQ:BVS Previous SymbolNASDAQ:BVS CIK1665988 WebN/A Phone(919) 474-6700FaxN/AEmployees1,200Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.54 million Net Margins-0.03% Pretax Margin-8.29% Return on Equity23.51% Return on Assets5.99% Debt Debt-to-Equity Ratio1.66 Current Ratio1.43 Quick Ratio0.89 Sales & Book Value Annual Sales$573.28 million Price / Sales0.99 Cash Flow$1.01 per share Price / Cash Flow6.81 Book Value$2.28 per share Price / Book3.02Miscellaneous Outstanding Shares82,140,000Free Float55,036,000Market Cap$565.94 million OptionableN/A Beta0.83 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:BVS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredGold Hit $3,500. Here’s What’s Next…Gold just smashed through $3,500—and some experts believe that’s only the beginning. With big banks like Goldm...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioventus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioventus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.